Table 1 Clinicopathological characteristics of patients at diagnosis of epithelial ovarian cancer
Characteristics | All (n=128, %) | BRCA mutation (n=51, %) | BRCA wild-type (n=77, %) | P |
|---|---|---|---|---|
Age, years | ||||
 Mean ± SD | 56.4 ± 10.3 | 54.7 ± 9.9 | 57.5 ± 10.4 | 0.130 |
 <50 | 39 (30.5) | 20 (39.2) | 19 (24.7) | 0.080 |
 ≥50 | 89 (69.5) | 31 (60.8) | 58 (75.3) | |
BMI, kg/m2 | ||||
 Mean ± SD | 23.4 ± 3.5 | 23.2 ± 3.7 | 23.6 ± 3.5 | 0.576 |
CA-125, IU/ml | ||||
 Median (range) | 921.5 (13.0−10000.0) | 795.0 (34.9−9926.0) | 1296.0 (13.0−10000.0) | 0.724 |
FIGO stage | Â | Â | Â | 0.077 |
 III | 77 (60.2) | 38 (74.5) | 39 (50.6) | 0.007 |
  IIIA1 | 4 (3.1) | 3 (5.9) | 1 (1.3) |  |
  IIIA2 | 4 (3.1) | 1 (2.0) | 3 (3.9) | |
  IIIB | 12 (9.4) | 5 (9.8) | 7 (9.1) | |
  IIIC | 57 (44.5) | 29 (56.9) | 28 (36.4) | |
 IV | 51 (39.8) | 13 (25.5) | 38 (49.4) | 0.007 |
  IVA | 6 (4.7) | 1 (2.0) | 5 (6.5) |  |
  IVB | 45 (35.2) | 12 (23.5) | 33 (42.9) | |
Primary treatment strategy | Â | Â | Â | 0.846 |
 PDS | 79 (61.7) | 32 (62.7) | 47 (61.0) |  |
 NAC | 49 (38.3) | 19 (37.3) | 30 (39.0) | |
Residual tumor after PDS/IDS | Â | Â | Â | 0.192 |
 Optimal debulking | 109 (85.2) | 46 (90.2) | 63 (81.8) |  |
 Suboptimal debulking | 19 (14.8) | 5 (9.8) | 14 (18.2) | |
Recurrence | ||||
 No | 39 (30.5) | 20 (39.2) | 19 (24.7) | 0.080 |
 Yes | 89 (69.5) | 31 (60.8) | 58 (75.3) | |
 Platinum-sensitive recurrence | 62 (48.4) | 25 (49.0) | 37 (48.1) | 0.099 |
 Platinum-resistant recurrence | 27 (21.1) | 6 (11.8) | 21 (27.3) | |
BRCA mutation | ||||
 BRCA1 | 37 (28.9) | 37 (72.5) |  |  |
 BRCA2 | 14 (10.9) | 14 (27.5) |  | |
 Both | 0 (0) | 0 (0) |  | |
Interval between diagnosis and genetic test, months | ||||
 Median (range) | 3.5 (0−22.7) | 2.6 (0−22.4) | 4.3 (0.1−22.7) | 0.065 |